AGIOS PHARMACEUTICALS, INC. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Agios reported Q2 2026 net product revenues of $44.7M (vs. $12.5M YoY), driven by U.S. AQVESME launch in thalassemia with 442 cumulative prescriptions as of June 30, 2026. FDA granted Priority Review for mitapivat sNDA in sickle cell disease with PDUFA goal date November 1, 2026. Company licensed cevidoplenib from Oscotec for $25.0M upfront (potential $1.0B peak U.S. sales in ITP) and advanced AG-236 into Phase 2/3 for polycythemia vera. Cash position: $964.8M (vs. $1,164.4M Dec 31, 2025); net loss: $100.7M vs. $112.0M YoY.
Why this rating
Strong commercial traction, regulatory catalyst (sickle cell Priority Review), pipeline diversification meaningful at ~$2B market cap; cash sufficient for 2+ years execution.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.